Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Administrative Officer | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,062 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-03 · Tax withholding · Disposed 8,528 · Balance 177,321 F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Row 2 · 2026-06-04 · Sale · Disposed 10,259 · Balance 167,062 F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 21:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 10,259 | $22.27 | $228,467.93 |
DisclosureSEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 2 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,062 F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:57 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 8,528 | $22.32 | $190,344.96 |
DisclosureSEC source: 0001628280-26-041330 · wk-form4_1780696617.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,321 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:02 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 54,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008078 · wk-form4_1771016534.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,849 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 23:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 13,137 | $20.53 | $269,702.61 |
DisclosureSEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 2 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,303 F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 17,134 | $20.54 | $351,932.36 |
DisclosureSEC source: 0001628280-26-005157 · wk-form4_1770161039.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,440 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 21:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 14,376 | $26.24 | $377,226.24 |
DisclosureSEC source: 0001396814-25-000068 · wk-form4_1749159376.xml · nonDerivative · entry 2 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,574 Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 6,162 | $26.40 | $162,676.80 |
DisclosureSEC source: 0001396814-25-000068 · wk-form4_1749159376.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,950 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 23:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 79,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000032 · wk-form4_1738711548.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,112 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,452 | $28.38 | $211,487.76 |
DisclosureSEC source: 0001396814-24-000074 · wk-form4_1718316760.xml · nonDerivative · entry 2 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,912 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 54,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000074 · wk-form4_1718316760.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,364 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:09 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 3,011 | $30.89 | $93,009.79 |
DisclosureSEC source: 0001396814-24-000053 · wk-form4_1717621763.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,064 F1 · kind: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:59 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 33,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000018 · wk-form4_1707343183.xml · nonDerivative · entry 1 WILLIAMS KRISTEN · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,075 F1 · shares: Represents restricted stock units that vest on February 1, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038032 · doc4.xml · derivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2033-06-14 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,467 | $37.03 | $239,473.01 |
DisclosureSEC source: 0001209191-23-038032 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,375 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 10,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038032 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,842 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,357 | $37.87 | $51,382.81 |
DisclosureSEC source: 0001209191-23-035265 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,892 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,301 | $38.99 | $50,727.29 |
DisclosureSEC source: 0001209191-23-035265 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,249 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 24,800 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035233 · doc4.xml · derivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2032-06-08 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,550 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 23:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,649 | $59.51 | $276,661.99 |
DisclosureSEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,650 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,969 | $61.37 | $243,593.41 |
DisclosureSEC source: 0001209191-22-035233 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,299 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,188 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 7 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,685 Underlying: Common Stock · 2,188 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,112 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 6 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,560 Underlying: Common Stock · 2,112 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,953 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · derivative · entry 5 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,953 Underlying: Common Stock · 2,953 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,253 | $72.67 | $527,075.51 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,188 | $47.65 | $104,258.20 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,112 | $43.54 | $91,956.48 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,953 | $38.35 | $113,247.55 |
DisclosureSEC source: 0001209191-22-020788 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,050 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · derivative · entry 7 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,906 Underlying: Common Stock · 2,050 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $67.07 | $134,140.00 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 5 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.015 to $67.160, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 50 | $65.00 | $3,250.00 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,050 | $38.35 | $78,617.50 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · derivative · entry 6 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,956 Underlying: Common Stock · 10 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| February 16, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 10 | $65.00 | $650.00 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2022 Filed Mar 1, 2022 22:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 10 | $38.35 | $383.50 |
DisclosureSEC source: 0001209191-22-014194 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-009400 · doc4.xml · derivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,966 Underlying: Common Stock · 800 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 800 | $65.18 | $52,144.00 |
DisclosureSEC source: 0001209191-22-009400 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.10 to $65.32, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 800 | $38.35 | $30,680.00 |
DisclosureSEC source: 0001209191-22-009400 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-007755 · doc4.xml · derivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,766 Underlying: Common Stock · 1,000 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $65.18 | $65,180.00 |
DisclosureSEC source: 0001209191-22-007755 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.045 to $65.330, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,000 | $38.35 | $38,350.00 |
DisclosureSEC source: 0001209191-22-007755 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-004795 · doc4.xml · derivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,766 Underlying: Common Stock · 200 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 200 | $65.41 | $13,082.00 |
DisclosureSEC source: 0001209191-22-004795 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.365 to $65.460, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 200 | $38.35 | $7,670.00 |
DisclosureSEC source: 0001209191-22-004795 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,199 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 13 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,966 Underlying: Common Stock · 2,199 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,199 | $65.51 | $144,056.49 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 8 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.055 to $65.880, inclusive. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,199 | $38.35 | $84,331.65 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 7 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,127 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 12 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,873 Underlying: Common Stock · 13,127 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,338 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 11 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,672 Underlying: Common Stock · 6,338 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 10 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,165 Underlying: Common Stock · 2,600 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.